Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

BMC Nephrology

Research

Toshitaka Yajima¹  Toyoaki Murohara²  Charles V. Pollack³  Eiichiro Kanda⁴  Anjay Rastogi⁵  Gengshi Chen⁶  Krister Järbrink⁷  Eva Lesén⁷  Matthew Arnold⁸  Abiy Agiro⁹ 

[1] CVRM TA, Medical Affairs, AstraZeneca, Tokyo, Japan;Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan;Department of Emergency Medicine, University of Mississippi School of Medicine, Jackson, MS, USA;Department of Medical Science, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192, Okayama, Japan;Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA;Health Economics & Payer Evidence, AstraZeneca, Cambridge, UK;Medical & Payer Evidence, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden;Real World Science and Digital, AstraZeneca, Cambridge, UK;US Evidence, Medical Affairs, BioPharmaceuticals R&D, AstraZeneca, Wilmington, DE, USA;

关键词: Hyperkalemia;    Heart failure;    Chronic kidney disease;    Guideline-directed medical therapy;    Potassium binder;   

DOI  :  10.1186/s12882-022-03054-5

 received in 2022-09-28, accepted in 2022-12-28,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundHyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF and/or CKD.MethodsThis observational study utilized data from hospital records, claims, and health registers from the US (Optum’s de-identified Market Clarity Data) and Japan (Medical Data Vision). Included patients had an index episode of HK between July 2019 and September 2021 (US), or May 2020 and September 2021 (Japan), with prior diagnosis of HF or CKD (stage 3 or 4), and RAASi use. Risk of a cardiorenal composite outcome (HF emergency visit, HF hospitalization, or progression to end-stage kidney disease) was determined in patients who discontinued RAASi, down-titrated their dose by > 25%, or maintained or up-titrated their dose following the HK episode.ResultsA total of 15,488 and 6020 patients were included from the US and Japan, respectively. Prior to the episode of HK, 59% (US) and 27% (Japan) of patients had achieved > 50% target RAASi dose. Following the episode of HK, 33% (US) and 32% (Japan) of patients did not fill a new RAASi prescription. Risk of the cardiorenal outcome at 6 months was higher in patients who discontinued or down-titrated versus maintained or up-titrated RAASi treatment both in the US (17.5, 18.3, and 10.6%; p <  0.001) and in Japan (19.7, 20.0, and 15.1%; p <  0.001).ConclusionHK-related RAASi discontinuation or down-titration was associated with higher risk of cardiorenal events versus maintained or up-titrated RAASi.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2022_35_Article_IEq512.gif

41116_2022_35_Article_IEq510.gif

41116_2022_35_Article_IEq507.gif

Fig. 27

41116_2022_35_Article_IEq503.gif

41116_2022_35_Article_IEq499.gif

Fig. 24

41116_2022_35_Article_IEq487.gif

Fig. 21